MétaCan
Menu
← Back to cohort
Record W4407285903 · doi:10.1093/jcag/gwae059.127

A127 PEMBROLIZUMAB-ASSOCIATED IMMUNE CHECKPOINT INHIBITOR GASTRITIS AND DUODENITIS: A CASE REPORT

2025· article· en· W4407285903 on OpenAlexaff
Stephanie Canning, Moira Rushton

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsOttawa Hospital
Fundersnot available
KeywordsPembrolizumabMedicineDuodenitisGastritisImmune systemImmunologyGastroenterologyImmunotherapyHelicobacter pylori

Abstract

fetched live from OpenAlex

Abstract Background Advancements in immunotherapy have revolutionized the treatment of cancer. However, innate to their mechanism of action, these therapies are associated with various immune-related adverse effects which present challenges to their use. While immune checkpoint inhibitor-associated colitis is the most common gastrointestinal toxicity, upper gastrointestinal involvement, such as esophagitis, gastritis, and duodenitis remains considerably rare. Aims The aim of this case report is to describe a severe case of immune checkpoint inhibitor-associated gastritis/duodenitis and highlight some of the challenges linked with its diagnosis and management. Methods We performed a retrospective chart review of the described patient and conducted a review of the relevant literature. Results A 65-year-old female was diagnosed with triple-negative, invasive ductal carcinoma and had been undergoing adjuvant treatment with pembrolizumab. Ten months after initiating therapy, she presented with epigastric pain, nausea/vomiting, and poor appetite. She subsequently underwent an esophagogastroduodenoscopy (EGD) which revealed a firm and friable stomach with thickened mucosa and significant edema of the duodenal cap. An initial review of the biopsies taken during upper endoscopy demonstrated non-specific gastric and duodenal inflammation without a definitive diagnosis. However, a subsequent review at consensus rounds suggested severe immune checkpoint inhibitor-associated gastritis/duodenitis and she was started on corticosteroid therapy. While her symptoms were refractory to high-dose intravenous methylprednisolone, she showed marked improvement after two infusions of infliximab (5mg/kg and 10mg/kg, respectively). Conclusions This case highlights the importance of increasing awareness of immune checkpoint inhibitor-associated gastritis and duodenitis, involving a multidisciplinary team to help facilitate its diagnosis, and emphasizes the role of repeated doses of biologic therapy in steroid-refractory cases. Figure 1. Endoscopic findings of immune checkpoint inhibitor-associated gastritis (1) Diffuse edema and friability in the gastric fundus. (2) Diffusely edematous gastric body with loss of the typical gastric folds. (3) Mild edema along the gastric antrum. (4) Normal appearing duodenal mucosa in the second portion of the duodenum. Funding Agencies None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0050.003
Science and technology studies0.0030.002
Scholarly communication0.0020.004
Open science0.0010.003
Research integrity0.0060.005
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.237
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→